The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).84”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [30]
In the citing paper
“Elotuzumab has been proposed to function at least partially through upregulation of IL-2 production by T cells and stimulation of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC)68–70.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationVoskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citationCollins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citationPérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93
Cited by
Sorted by citations
Items 701–800 of 1,000
Choe, U., Pham, Q., Kim, Y. S., Yu, L. L., & Wang, T. T. Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-37040-0 · Cited by 11
Jreich, R., Zhang, H., Meng, Z., & Wang, F. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0164 · Cited by 11
Zabaleta, A., Blanco, L., Kim, P. S., Bisht, K. K., Wang, H., de Velde, H. J. V., Lasa, M., Tamariz‐Amador, L., Rodríguez‐Otero, P., Miguel, J. F. S., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19784 · Cited by 11
Avigan, Z. M., Mitsiades, C. S., & Laganà, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.001 · Cited by 11
Jung, S., Koh, Y., Kim, M. K., Kim, J. S., Moon, J., Min, C., Yoon, D. H., Yoon, S. S., Lee, J., Hong, C. M., et al. (2025) · Blood Research · doi:10.1007/s44313-025-00055-9 · Cited by 11
How is patient care for multiple myeloma advancing?
Stavric, S. G., Bonello, F., Bringhen, S., Boccadoro, M., & Larocca, A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1326814 · Cited by 11
Montefusco, V., Corso, A., Galli, M., Ardoino, I., Pezzatti, S., Carniti, C., Patriarca, F. F., Gherlinzoni, F., Zambello, R., Sammassimo, S., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.16287 · Cited by 12
Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis
Doren, L. V., & Lentzsch, S. (2020) · Acta Haematologica · doi:10.1159/000507724 · Cited by 11
A review on the treatment of multiple myeloma with small molecular agents in the past five years
Zhang, Z., Liu, X., Zhao, L., Zhou, Y., Shi, J., Chen, W., & Li, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114053 · Cited by 11
Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
Guo, R., Lu, W., Zhang, Y., Cao, X., Jin, X. K., & Zhao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839097 · Cited by 12
Beksaç, M., Špıčka, I., Hájek, R., Bringhen, S., Jelı́nek, T., Martin, T., Mikala, G., Moreau, P., Symeonidis, A. S., Rawlings, A. M., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106948 · Cited by 11
Self-citationMinor clone of del(17p) provides a reservoir for relapse in multiple myeloma
Cui, J., Lv, R., Yu, T., Yan, W., Xu, J., Fan, H., Li, L., Liu, Y., Du, C., Deng, S., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283533 · Cited by 11
Next-Generation Therapies for Multiple Myeloma
Meermeier, E. W., Bergsagel, P. L., & Chesi, M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-014236 · Cited by 12
Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Terpos, E., Suzan, F., & Goldschmidt, H. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.021 · Cited by 11
Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase
Holstein, S. A., Hillengaß, J., & McCarthy, P. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9637 · Cited by 11
Kocoglu, M. H., & Badros, A. Z. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1756258 · Cited by 11
Borrelli, E. P., & McGladrigan, C. G. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220941937 · Cited by 11
Current developments in the combination therapy of relapsed/refractory multiple myeloma
Maples, K. T., Joseph, N. S., & Harvey, R. D. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1828071 · Cited by 11
Barilà, G., Rizzi, R., Zambello, R., & Musto, P. (2021) · Pharmaceuticals · doi:10.3390/ph14010040 · Cited by 11
Boosting Immunity against Multiple Myeloma
Lopes, R., Ferreira, B. V., Caetano, J., Barahona, F., Carneiro, E. A., & Joao, C. M. (2021) · Cancers · doi:10.3390/cancers13061221 · Cited by 11
Sorafenib for the treatment of multiple myeloma
Gentile, M., Martino, M. V., Recchia, A. G., Vigna, E., Morabito, L., & Morabito, F. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1169272 · Cited by 11
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma
Veltri, L. W., Milton, D. R., Delgado, R., Shah, N. D., Patel, K. K., Nieto, Y. L., Kebriaei, P., Popat, U., Parmar, S., Oran, B., et al. (2017) · Cancer · doi:10.1002/cncr.30770 · Cited by 11
Self-citationImmunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noonan, K. A., & Colson, K. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.005 · Cited by 12
Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma
Saraceni, M. M., Scott, E. C., Maziarz, R. T., Siegel, M. B., Bassale, S., Jiing, S., & Medvedova, E. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.10.008 · Cited by 11
Pourmoussa, A., Spielberger, R. T., Cai, J., Khoshbin, O., Farol, L. T., Cao, T. M., & Sahebi, F. (2019) · The Permanente Journal · doi:10.7812/tpp/19.012 · Cited by 11
Yee, A. J., Laubach, J. P., Campagnaro, E. L., Lipe, B. C., Nadeem, O., Friedman, R. S., Cole, C. E., O’Donnell, E., Bianchi, G., Branagan, A. R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014717 · Cited by 10
Self-citationEmerging roles of SLAMF7 in immune cells and related diseases
Zhang, Z., Zhang, Y., Chen, Z., & Xia, L. (2025) · Innate Immunity · doi:10.1177/17534259251326700 · Cited by 10
Liu, A., Bai, P., You, H., Zhuang, Z., Tian, F., Weng, H., Wei, X., Tang, L., Wang, L., Liu, C., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.02.015 · Cited by 10
Liu, L., Zhao, N., Xu, W., Sheng, Z., & Wang, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0286-x · Cited by 10
Innate Immune Stimulation in Cancer Therapy
Duewell, P., Heidegger, S. M., & Kobold, S. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.002 · Cited by 10
Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells
Shah, U. A., & Smith, E. L. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000379 · Cited by 11
Morabito, F., Zamagni, E., Conticello, C., Pavone, V., Palmieri, S., Bringhen, S., Galli, M., Mangiacavalli, S., Derudas, D., Rossi, E., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13723 · Cited by 10
Dimopoulos, M. A., Mikhael, J. R., Terpos, E., Leleu, X. P., Moreau, P., Bladé, J., Kim, J. S., Stockerl-Goldstein, K. E., & Richardson, P. G. G. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221088458 · Cited by 10
Self-citationZhou, T., Guan, Y., Sun, L., & Liu, W. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112088 · Cited by 10
Klausz, K., Cieker, M., Kellner, C., Oberg, H., Kabelitz, D., Valerius, T., Burger, R., Gramatzki, M., & Peipp, M. (2017) · Oncotarget · doi:10.18632/oncotarget.20641 · Cited by 10
Greil, C., Ihorst, G., Gaiser, F., Salzer, U., Bissé, E., Kastritis, E., Ludwig, H., Wäsch, R., & Engelhardt, M. M. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12958 · Cited by 10
Morgan, G. J., & Rasche, L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1489718 · Cited by 10
Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma
Rafei, H., Haroun, F., & Tabbara, I. A. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000506 · Cited by 10
Campioni, M., Agirrezabal, I., Hájek, R., Minařík, J., Pour, L., Spicka, I., Gonzalez‐McQuire, S., Jandová, P., & Maisnar, V. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01122-6 · Cited by 10
Self-citationImmunotherapy in multiple myeloma: when, where, and for who?
Verkleij, C. P. M., Korst, C. L. B. M., & van de Donk, N. W. C. J. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000677 · Cited by 10
Monoclonal antibodies as an addition to current myeloma therapy strategies
Jullien, M., Touzeau, C., & Moreau, P. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1837627 · Cited by 10
Self-citationImmunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
Fang, Y., & Hou, J. (2021) · Military Medical Research · doi:10.1186/s40779-021-00302-x · Cited by 10
Rice, M. S., Naeger, S., & Singh, E. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00146-4 · Cited by 10
Straßl, I., Schreder, M., Steiner, N., Rudzki, J. D., Agis, H., Kunz, T., Müser, N., Willenbacher, W., Petzer, A. L., Neumeister, P., et al. (2021) · Cancers · doi:10.3390/cancers13184701 · Cited by 10
Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
Ray, E. L., Jagannath, S., & Palumbo, A. P. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2016.1119041 · Cited by 10
Self-citationRole of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma
Olteanu, H. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2015.09.009 · Cited by 10
Clark, C. A., Cornell, R. F., Scott, E. C., Chung, J., & Costa, L. J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24478 · Cited by 10
Passey, C., Mora, J. R., Dodge, R. W., Gibiansky, L. V., Sheng, J., Roy, A., Bello, A., & Gupta, M. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0033-9 · Cited by 10
Safety issues and management of toxicities associated with new treatments for multiple myeloma
Brioli, A., Mügge, L., Hochhaus, A., & von Lilienfeld‐Toal, M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1284584 · Cited by 10
Kobayashi, T., Miura, M., Niioka, T., Abumiya, M., Ito, F., Kobayashi, I., Ikeda, S., Yoshioka, T., Kameoka, Y., & Takahashi, N. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000499 · Cited by 10
Bosseler, M., Marani, V., Broukou, A., Lequeux, A., Kaoma, T., Schlesser, V., François, J.-H., Palissot, V., Berchem, G., Aouali, N., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061551 · Cited by 10
Multiple myeloma: Current and future management in the aging population
Fotiou, D., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.04.015 · Cited by 10
Self-citationHow I Manage Frontline Transplant-Ineligible Multiple Myeloma
Derudas, D., Capraro, F., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8956 · Cited by 11
Lahuerta, J. J., Paiva, B., Ubieto, A. J., Sánchez-Pina, J. M., Mateos, M., Bladé, J., & Miguel, J. F. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003996 · Cited by 10
Self-citationHeat shock proteins as a new, promising target of multiple myeloma therapy
Grosicki, S., Bednarczyk, M., & Janikowska, G. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1711730 · Cited by 10
Self-citationEvidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma
Bertolotti, P., Pierre, A., Rome, S., & Faiman, B. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.05.008 · Cited by 9
Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4
Ma, N., Liu, H., Zhang, Y., Liu, W., Liang, Z., Wang, Q., Yuhua, S., Wang, L., Li, Y., Ren, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927804 · Cited by 9
Richardson, P. G. G., Beksaç, M., Oriol, A., Lindsay, J., Schjesvold, F. H., Galli, M., Yağcı, M., Larocca, A., Weisel, K. C., Yu, X., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.14365 · Cited by 9
Self-citationPomalidomide in the Management of Relapsed Multiple Myeloma
Touzeau, C., & Moreau, P. (2016) · Future Oncology · doi:10.2217/fon-2016-0184 · Cited by 9
Self-citationMonoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis
Godara, A., & Palladini, G. O. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.005 · Cited by 9
Preston, S. E. J., Émond, A., Pettersson, F., Dupéré-Richer, D., Abraham, M. J., Riva, A., Kinal, M., Rys, R. N., Johnson, N. A., Mann, K. K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0216 · Cited by 9
Osterhoff, G., Kreinest, M., Kuhnt, T., Pohlenz, C., Müller-Broich, J. D., Röllig, C., Teipel, R., Scheyerer, M. J., Schnake, K. J., Spiegl, U. J. A., et al. (2023) · Global Spine Journal · doi:10.1177/21925682221143732 · Cited by 9
Self-citationA Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
Niazi, S. K. (2023) · Pharmaceuticals · doi:10.3390/ph16111556 · Cited by 10
Wang, Y.-H., Hagiwara, S., Kazama, H., Iizuka, Y., Tanaka, N., & Tanaka, J. (2024) · Journal of Immunology Research · doi:10.1155/2024/1429879 · Cited by 9
Tambourine, B. M., Sadeghi, A., Yang, J., Stockl, K. M., Lew, H. C., Solow, B. K., & Tran, J. N. (2016) · Europe PMC (PubMed Central) · Cited by 9
Ely, S. A., Forsberg, P. A., Ouansafi, I., Rossi, A., Modin, A., Pearse, R. N., Pekle, K. A., Perry, A., Coleman, M., Jayabalan, D. S., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.09.010 · Cited by 9
Present and Future of Immunotherapy in the Management of Multiple Myeloma
Baljević, M., & Holstein, S. A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00111 · Cited by 9
Abdallah, A.-O. A., Sigle, M., Mohyuddin, G. R., Coggins, E., Remker, C., Shune, L. O., Mahmoudjafari, Z., McGuirk, J. P., & Ganguly, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.09.002 · Cited by 9
Usui, Y., Nakano, H., Komatsu, J., Nakamichi, K., Saijo, M., Takano, S., Kamiya, K., Hamaguchi, T., & Yamada, M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1765237 · Cited by 9
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
Morè, S., Petrucci, M. T., Corvatta, L., Fazio, F., Offidani, M., & Olivieri, A. (2020) · Pharmaceuticals · doi:10.3390/ph13120426 · Cited by 9
Huynh, T., Corre, E., Lemonnier, M.-P., Duléry, R., Marjanovic, Z., Jaff, N., Lapusan, S., Mohty, M., Garderet, L., & Coppo, P. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1907373 · Cited by 9
Ide, T., Osawa, M., Sanghavi, K., & Vezina, H. E. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04365-4 · Cited by 9
Steps towards a Multiple Myeloma Cure?
Gozzetti, A., & Bocchia, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091451 · Cited by 9
Lee, J. H., Kim, S., Kim, H. R., Min, C., Lee, J., Shin, H., Jo, J., Lee, J. Y., Moon, J. H., & Kım, K. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03479-6 · Cited by 9
Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways
Hashemi, M., Roshanzamir, S. M., Paskeh, M. D. A., Karimian, S. S., Mahdavi, M. S., Kheirabad, S. K., Naeemi, S., Taheriazam, A., Salimimoghadam, S., Entezari, M., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175380 · Cited by 10
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates
Robak, P. J., & Robak, T. (2016) · BioDrugs · doi:10.1007/s40259-016-0165-6 · Cited by 9
Novel Combination Treatments in Multiple Myeloma.
Nooka, A. K., & Lonial, S. (2016) · PubMed · Cited by 9
Self-citationTreatment of Relapsed/Refractory Multiple Myeloma
Neri, P. E., Bahlis, N. J., Paba‐Prada, C. E., & Richardson, P. G. G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_10 · Cited by 10
Self-citationShould minimal residual disease negativity be the end point of myeloma therapy?
Anderson, K. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016000117 · Cited by 9
Self-citationChanges in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
Ravi, P. K., Kumar, S. K., Gonsalves, W. I., Buadi, F. K., Lacy, M. Q., Go, R. S., Dispenzieri, A. A., Kapoor, P., Lust, J. A., Dingli, D., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.46 · Cited by 9
Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach
González‐Calle, V., Keane, N., Braggio, E., & Fonseca, R. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.021 · Cited by 9
Atchison, D. K., & Humes, H. D. (2017) · Clinical Nephrology - Case Studies · doi:10.5414/cncs109165 · Cited by 9
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
Eleutherakis‐Papaiakovou, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1685879 · Cited by 9
Self-citationAntibody therapies for multiple myeloma
Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., & Terpos, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1717464 · Cited by 9
Suzuki, K. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02841-w · Cited by 9
Ninkovic, S., & Quach, H. (2020) · Cancers · doi:10.3390/cancers12113488 · Cited by 9
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Podar, K., & Pecherstorfer, M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340942 · Cited by 9
The molecular biology of multiple myeloma
Chng, W. J., & Bergsagel, P. L. (2019) · Wiley eBooks · doi:10.1002/9781119252863.ch10 · Cited by 9
Promise of Immune Therapies in Multiple Myeloma
Anderson, K. C. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00311 · Cited by 9
Self-citationWhat The Princess Bride Teaches Us About Outcomes in Multiple Myeloma
D’Souza, A., & Lonial, S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01137 · Cited by 9
Self-citationYuan, F., Wei, J., Cheng, Y. H., Wang, F., Gu, M., Li, Y., Zhao, X. Y., Sun, H., Ban, R., Zhou, J., et al. (2023) · Inflammation · doi:10.1007/s10753-023-01926-y · Cited by 8
Promising immunotherapeutic approaches for primary effusion lymphoma
Panaampon, J., & Okada, S. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00242 · Cited by 9
Sequencing of nontransplant treatments in multiple myeloma patients with active disease
Yee, A. J., & Raje, N. S. (2016) · Hematology · doi:10.1182/asheducation-2016.1.495 · Cited by 8
Sanz, I. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40109 · Cited by 8
Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies
Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79999 · Cited by 8
Morabito, F., Zamagni, E., Conticello, C., Pavone, V., Palmieri, S., Bringhen, S., Galli, M., Mangiacavalli, S., Derudas, D., Rossi, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890376 · Cited by 8
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Solimando, A. G., Krebs, M., Desantis, V., Marziliano, D., Caradonna, I. C., Morizio, A., Argentiero, A., Shahini, E., & Bittrich, M. (2023) · Biomedicines · doi:10.3390/biomedicines11072087 · Cited by 9
Artificial intelligence in serum protein electrophoresis: history, state of the art, and perspective
He, H., Wang, L., Wang, X., & Zhang, M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2274325 · Cited by 8
Parrondo, R. D., LaPlant, B. R., Elliott, J. B., Fernandez, A., Flott, C., Arrington, D. A. H., Chapin, D., Brown, J., Das, S., Roy, V., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01134-3 · Cited by 8
Diagnostic Advances in Multiple Myeloma
Barley, K. M., & Chari, A. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0314-5 · Cited by 8
Metadata
- Authors
- Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
- Affiliations
- Dalhousie University (CA)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Medical University of Silesia (PL)
- Centre Hospitalier Universitaire de Nantes (FR)
- Tel Aviv University (IL)
- University of Alberta (CA)
- Princess Margaret Cancer Centre (CA)
- Alfred Health (AU)
- Barts Health NHS Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Kyoto Prefectural University of Medicine (JP)
- Technische Universität Dresden (DE)
- Universitätsklinikum Würzburg (DE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- AbbVie Biotherapeutics (United States) (US)
- National Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 621-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2201190784
- Semantic Scholar
- fb9d8d9019089b66fbe8ecd85963014c537e649e
- Cited by
- 1,322
- References
- 15
- Citations by year
- 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
- FWCI
- 139.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- AbbVie Biotherapeutics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
